PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development and oral therapies based on defined bacterial consortia that is in phase 3 clinical stage. PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.

Currency in USD	2025
Income Tax Expense	-842 Thousand
Net Income	-109.74 Million
Eps	-0.46
Epsdiluted	-0.46
Weighted Average Shs Out	240.79 Million
Weighted Average Shs Out Dil	240.79 Million
Depreciation And Amortization	3.35 Million
Interest Expense	45.78 Million
Ebit	-65.15 Million
Interest Income	13.05 Million
Net Interest Income	-32.73 Million
Period	FY
Ebitda	-95.18 Million
Net Cash Provided By Operating Activities	N/A
Source	yahoo

PureTech Health plc Annual Reports (10-K)